Best pharmaceutical companies in Emeryville, CA

Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Ligand business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Ligand goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company. Ligand business model is based on doing what we do best: drug discovery, early-stage drug development, product reformulation and partnering. Ligand partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) to ultimately generate Ligand revenue.

Catalent Pharma Solutions, Inc. provides drug delivery technologies and outsourced development, manufacturing, and packaging services to the pharmaceutical, biotechnology, and consumer health industry worldwide. It operates in four segments: Development and Clinical Services, Oral Technologies, Sterile Technologies, and Packaging Services. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management for drugs and biologics in clinical trials. It also offers analytical chemical and cell-based testing and scientific services, respiratory products formulation and manufacturing, regulatory consulting, and biologics proprietary expression technology, and product development. The Oral Technologies segment provides formulation, development, and manufacturing services for the oral dose forms. Its oral drug delivery technologies include proprietary delivery technologies for drugs and consumer health products. This segment also offers formulation, development, and manufacturing services for conventional oral dose forms, including controlled release formulations, as well as immediate release tablets and capsules. The Sterile Technologies segment provides proprietary and traditional dose forms for separate routes of administration. It offers formulation and development for injectable drugs; and fills drugs or biologics into vials, pre-filled syringes, bags, and other sterile delivery formats. This segment's blow-fill-seal technology provides integrated dose form creation and filling of sterile liquids in a single process for respiratory, ophthalmic, and other routes of administration. The Packaging Services segment offers packaging services for pharmaceuticals, biologics, consumer health, and veterinary products, which include packaging drugs in blisters, bottles, pouches, and unit doses; and printed components, such as creating package inserts or folding cartons. The company is based in Somerset, New Jersey.

IPS-Integrated Project Services, LLC is one of the fastest-growing companies in the A/E/C industry with a global reach that spans over ten countries in four continents

Grifols is a global healthcare company. Grifols operates in three segments: Bioscience, Hospital, and Diagnostic. The Bioscience segment engages in the research, development, production, and commercialization of plasma derivates. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing diagnostics products for laboratory analysis, including products for hospital blood banks and transfusion centers.

Gilead Palo Alto, Inc. develops and commercializes small molecule drugs for the treatment of cardiovascular diseases. It develops advances in molecular biology and genetics to identify mechanisms of cardiovascular diseases and targets for drug discovery. The company offers Ranexa (ranolazine extended-release tablets), which is used for the treatment of chronic angina; and Lexiscan (regadenoson) injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging (MPI). Its products under clinical development comprise Tecadenoson, which is in Phase III clinical trials product for the potential reduction of rapid heart rate during acute atrial arrhythmias, and in Phase II clinical trials for acute atrial fibrillation; Adentri, a Phase III clinical studies product for heart failure; CVT-6883, a Phase I clinical trial product to treat cardiopulmonary diseases; and CVT-3619, a Phase I clinical studies drug for diabetes/metabolic syndrome. The company s products under preclinical trials include Tecadenoson for atrial fibrillation; CVT-10,216 to treat alcohol addicted patients; Late I for the treatment of coronary artery disease; A2A antagonist for chemical dependence; ABCA1/ApoA-I to treat atherosclerosis; and Drug-Eluting Stent Program for the treatment of restenosis. The company has collaborative partnerships with Biogen Idec Inc.; Astellas Pharma, Inc.; Menarini Group; and Roche Palo Alto LLC. Gilead Palo Alto, Inc. was formerly known as CV Therapeutics, Inc. and changed its name to Gilead Palo Alto, Inc. in January 2009. The company was incorporated in 1990 and is based in Foster City, California. As of April 14, 2009, Gilead Palo Alto, Inc. operates as a subsidiary of Gilead Sciences Inc.